-

Fresenius Kabi Selected for Second Consecutive Year to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi has been selected to exhibit its Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine, Texas.

#FreseniusKabi Selected for Second Consecutive Year to Exhibit the #Ivenix Infusion System at the @VizientInc Innovative Technology Exchange.

Share

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their product or service to supply chain and clinical leaders from Vizient’s provider customers and subject matter experts who serve on their supply councils. Each product or service will showcase how it improves clinical outcomes, enhances safety, or drives incremental improvements to health care delivery or business models.

The Ivenix Infusion System from Fresenius Kabi is designed to overcome deficiencies in legacy infusion pumps. The patented pumping technology in the Ivenix Infusion System delivers critical medications with flow that is continuously measured and controlled to help optimize fluid administration. The pump achieves accurate medication delivery with minimal impact from external conditions such as bag height, backpressure, and fluid viscosity, and it helps to prevent uncontrolled flow.

“The Ivenix Infusion System was designed to improve the patient experience and support efficient workflows for health care workers,” said Sue Niemeier, MHA, BSN, RN, vice president, clinical excellence at Fresenius Kabi USA. “We are excited to return to the Vizient Innovative Technology Exchange to demonstrate how the Ivenix Infusion System can help provide ease of use with infusion delivery.”

“The Exchange is an exciting part of the Vizient Innovative Technology Program, which results in Innovative Technology contract awards for the qualified products. This signals healthcare providers of a product’s unique qualities,” said Kelly Flaharty, senior director of contract services, Vizient. “With only a select number of suppliers invited to demonstrate their products, it’s an honor to be invited.”

The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in injectable medicines, biosimilars, and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Joanie Clougherty, 614-717-5741
joan.clougherty@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Joanie Clougherty, 614-717-5741
joan.clougherty@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has been certified by the Top Employers Institute as a 2026 Top Employer in the United States and North America. This affirms the company’s ongoing commitment to creating a positive work environment. Globally, Fresenius Kabi was certified as a Top Employer for 2026 in 13 countries and two regions. Since 2023, Fre...

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing. Frese...

Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi® (ustekinumab-aauz) in a 45 mg/0.5 mL single-dose vial for subcutaneous injection. Otulfi® is a prescription medicine and the brand name for Fresenius Kabi’s FDA-approved biosimilar of the reference product, Stelara® (ustekinumab). With this addition, Fresenius Kabi now offers...
Back to Newsroom